Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage<scp>II</scp>to<scp>III</scp>triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis-Reference-Cited by-同舟云学术

Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stageIItoIIItriple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis

Published:2022-04-19 Issue:4 Volume:151 Page:578-589
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Xiu Meng¹^ORCID,Zhang Pin¹^ORCID,Wang Xiang²,Fan Ying¹,Li Qiao¹^ORCID,Li Qing¹,Wang Jiayu¹^ORCID,Dong Lin³^ORCID,Luo Yang¹,Yuan Peng¹^ORCID,Ma Fei¹^ORCID,Xu Binghe¹^ORCID

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Breast Surgical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34022

Reference33 articles.

1. Triple-Negative Breast Cancer

2. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

4. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of apatinib combined with dose‐dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis;International Journal of Cancer;2023-09-07

2. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment;Expert Review of Anticancer Therapy;2023-05-31

3. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer;Biomedicine & Pharmacotherapy;2023-04

4. Synthesis and Discovery of Ligustrazine–Heterocycle Derivatives as Antitumor Agents;Frontiers in Chemistry;2022-07-25

5. Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials;Bioengineered;2022-06-01